Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00663832 · ClinicalTrials.gov registry record · Phase 1
A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT00663832 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 44 participants.
The verdict
NCT00663832, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This Phase Ib dose escalation study is designed to characterize the safety, tolerability and preliminary efficacy of i.v. panobinostat (LBH589) in combination with docetaxel and prednisone in the 1st line treatment of patients with hormone refractory prostate cancer.
Interventions
- DRUG LBH589 (i.v. panobinostat)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00663832
The ClinicalTrials.gov registry entry for NCT00663832 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LBH589 (i.v. panobinostat) is the first listed.
NCT00663832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00663832 about?
NCT00663832 is a clinical study titled "A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer". This Phase Ib dose escalation study is designed to characterize the safety, tolerability and preliminary efficacy of i.v. panobinostat (LBH589) in combination with docetaxel and prednisone in the 1st line treatment of patients with hormone refractory prostate cancer.
What is the current status of trial NCT00663832?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2008-02.
What interventions are being tested in trial NCT00663832?
The interventions under investigation include: LBH589 (i.v. panobinostat) (DRUG).
Who is sponsoring clinical trial NCT00663832?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.